Trials / Unknown
UnknownNCT04680624
Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients
Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patient - BOMOGUMIP
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Association pour la Recherche Clinique et Immunologique · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BOMOGUMIP is an interventional research with minimal risk and constraints (cat.2), exploratory, intra-individual, prospective, multi-site study. The main objective of this intra individual prospective study is to determine the evolution of microbial composition of fecal samples issued to 15 patients after 6 months of Brodalumab treatment. The population will consist of 15 adult patients suffering from moderate to severe skin psoriasis and starting, after having received a methotrexate treatment during at least 4 months, a brodalumab treatment in the first line of biological treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Fecal sample collection | During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected. |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
- First posted
- 2020-12-23
- Last updated
- 2020-12-23
Source: ClinicalTrials.gov record NCT04680624. Inclusion in this directory is not an endorsement.